IN2014CN04071A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04071A
IN2014CN04071A IN4071CHN2014A IN2014CN04071A IN 2014CN04071 A IN2014CN04071 A IN 2014CN04071A IN 4071CHN2014 A IN4071CHN2014 A IN 4071CHN2014A IN 2014CN04071 A IN2014CN04071 A IN 2014CN04071A
Authority
IN
India
Prior art keywords
antigen
tcdb
relates
tcda
difficile
Prior art date
Application number
Inventor
Maria Scarselli
Mariagrazia Pizza
Rosanna Leuzzi
Maria Arico
Manuele Martinelli
Gillian Douce
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201121149A external-priority patent/GB201121149D0/en
Priority claimed from GBGB1217321.7A external-priority patent/GB201217321D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014CN04071A publication Critical patent/IN2014CN04071A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to recombinant fragments of C. difficile TcdA and TcdB that may be used in the development of vaccines against C. difficile associated disease. More particularly it relates to combinations comprising a ToxB GT antigen and a TcdA antigen or a ToxA GT antigen and a TcdB antigen.
IN4071CHN2014 2011-12-08 2012-12-07 IN2014CN04071A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201121149A GB201121149D0 (en) 2011-12-08 2011-12-08 Clostridium difficile toxin-based vaccine
GBGB1217321.7A GB201217321D0 (en) 2012-09-27 2012-09-27 Vaccine
PCT/IB2012/002955 WO2013084071A2 (en) 2011-12-08 2012-12-07 Clostridium difficile toxin-based vaccine

Publications (1)

Publication Number Publication Date
IN2014CN04071A true IN2014CN04071A (en) 2015-10-23

Family

ID=47747684

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4071CHN2014 IN2014CN04071A (en) 2011-12-08 2012-12-07

Country Status (15)

Country Link
US (1) US9694063B2 (en)
EP (1) EP2788022B1 (en)
JP (1) JP6084631B2 (en)
KR (1) KR20140101835A (en)
CN (1) CN103974718A (en)
AU (1) AU2012349753A1 (en)
BR (1) BR112014013876A2 (en)
CA (1) CA2858519A1 (en)
ES (1) ES2704069T3 (en)
IL (1) IL232957A0 (en)
IN (1) IN2014CN04071A (en)
MX (1) MX2014006630A (en)
RU (1) RU2014127714A (en)
SG (1) SG11201402375VA (en)
WO (1) WO2013084071A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201911993UA (en) 2011-04-22 2020-02-27 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
AU2013319821A1 (en) * 2012-09-19 2015-02-26 Novartis Ag Clostridium difficile polypeptides as vaccine
BR122016023101B1 (en) 2012-10-21 2022-03-22 Pfizer Inc Polypeptide, immunogenic composition comprising it, as well as recombinant cell derived from Clostridium difficile
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
CA3156357A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
EP3160500B1 (en) * 2014-06-25 2019-08-21 GlaxoSmithKline Biologicals S.A. Clostridium difficile immunogenic composition
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
EP3972638A4 (en) * 2019-05-21 2023-09-13 The Regents Of The University Of California Vaccine compositions for clostridium difficile

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
ES2055785T3 (en) 1989-01-17 1994-09-01 Eniricerche Spa SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
ATE128628T1 (en) 1990-08-13 1995-10-15 American Cyanamid Co FIBER HEMAGGLUTININ FROM BORDETELLA PERTUSSIS AS A CARRIER FOR CONJUGATE VACCINE.
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
DK0761231T3 (en) 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccine containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
EP1041149B8 (en) 1994-10-24 2007-10-03 Allergan, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
CN1195297A (en) 1995-07-07 1998-10-07 奥拉瓦克斯有限公司 Clostridium difficile toxins as mucosal adjuvants
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
WO1998008540A1 (en) 1996-08-28 1998-03-05 Ophidian Pharmaceuticals, Inc. Multivalent vaccine for clostridium botulinum neurotoxin
JP5087758B2 (en) 1997-03-10 2012-12-05 オタワ ホスピタル リサーチ インスティチュート Use of nucleic acids containing unmethylated CpG dinucleotides as adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO1998059053A1 (en) * 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
ES2298316T3 (en) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. WATER OIL EMULSIONS CONTAINING SAPONINS.
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR100585408B1 (en) 1998-02-12 2006-06-01 와이어쓰 홀딩스 코포레이션 Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
CN1296416A (en) 1998-04-09 2001-05-23 史密丝克莱恩比彻姆生物有限公司 Adjuvant compositions
US20020009429A1 (en) * 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
CA2365915C (en) 1999-04-09 2015-11-24 Techlab, Inc. Recombinant toxin a/toxin b vaccine against clostridium difficile
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2001085748A2 (en) * 2000-05-10 2001-11-15 Glycodesign Inc. Designing modulators for glycosyltransferases
EP2277894A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
AU2002338233A1 (en) * 2001-03-30 2002-10-15 Basf Plant Science Gmbh Glucan chain length domains
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DK1450856T3 (en) 2001-09-14 2010-05-31 Cytos Biotechnology Ag Packaging of Immunostimulatory CpG in Virus-Like Particles, Method and Use
WO2004041857A2 (en) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
EP2857418B1 (en) 2004-02-06 2017-07-26 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
CA2592015A1 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
CN101500581B (en) 2006-06-08 2013-10-30 科内尔研究基金会 Codon-optimized DNA molecules encoding receptor binding domains of clostridium difficile toxins A and B, and methods of use thereof
ES2507553T3 (en) 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz LCT poisoning drug
EP2167119B1 (en) * 2007-06-14 2016-08-24 The Secretary of State for Health Chemically modified peptides with improved immunogenicity
WO2008156676A1 (en) * 2007-06-15 2008-12-24 President And Fellows Of Harvard College Methods and compositions for detecting and modulating o-glycosylation
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
AU2010215275B2 (en) 2009-02-20 2016-03-31 Micropharm Limited Antibodies to Clostridium difficile toxins
CA2772400A1 (en) * 2009-08-27 2011-03-17 Synaptic Research, Llc A novel protein delivery system to generate induced pluripotent stem (ips) cells or tissue-specific cells
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
US20120282274A1 (en) 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
JP2013512916A (en) * 2009-12-02 2013-04-18 タフツ ユニバーシティー Clostridium difficile non-toxic recombinant holotoxin as immunogen
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
JP5839411B2 (en) 2010-03-30 2016-01-06 フェニックス インク． High level expression of recombinant toxin protein
KR101820987B1 (en) * 2010-04-15 2018-01-22 프로제닉스 파머슈티컬스, 인코포레이티드 Antibodies for the treatment of clostridium difficile-associated infection and disease
WO2012028741A1 (en) 2010-09-03 2012-03-08 Intercell Ag Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
US8431361B2 (en) 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
SG10201911993UA (en) * 2011-04-22 2020-02-27 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
PL3564378T3 (en) 2011-05-27 2024-03-11 Glaxosmithkline Biologicals Sa Immunogenic composition
AR087716A1 (en) * 2011-08-31 2014-04-09 Valent Biosciences Corp COMPOSITIONS REGULATING GROWTH OF PLANTS, METHODS OF PREPARATION AND USES OF THE SAME
AR089797A1 (en) * 2012-01-27 2014-09-17 Merck Sharp & Dohme VACCINES AGAINST CLOSTRIDUM DIFFICILE THAT INCLUDE RECOMBINANT TOXINS
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Also Published As

Publication number Publication date
WO2013084071A2 (en) 2013-06-13
CA2858519A1 (en) 2013-06-13
US9694063B2 (en) 2017-07-04
CN103974718A (en) 2014-08-06
ES2704069T3 (en) 2019-03-14
JP2015500827A (en) 2015-01-08
US20150132333A1 (en) 2015-05-14
EP2788022A2 (en) 2014-10-15
WO2013084071A3 (en) 2013-11-07
AU2012349753A1 (en) 2014-06-19
EP2788022B1 (en) 2018-10-31
RU2014127714A (en) 2016-01-27
BR112014013876A2 (en) 2019-09-24
JP6084631B2 (en) 2017-02-22
KR20140101835A (en) 2014-08-20
SG11201402375VA (en) 2014-10-30
MX2014006630A (en) 2014-07-09
IL232957A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
IN2014CN04071A (en)
MX2013011479A (en) Anti-fgfr4 antibodies and methods of use.
IL242934B (en) Microbiota restoration therapy (mrt), compositions and methods of manufacture
TN2015000050A1 (en) Methods of treating a tauopathy
NZ715815A (en) High-stability t-cell receptor and preparation method and application thereof
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
MX2014004022A (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
MX2013015311A (en) Pcsk9-binding polypeptides and methods of use.
CR20150046A (en) ANTI-CD79B ANTIBODIES AND IMMUNOCATE PLAYERS
MX2014002053A (en) Anti-mcsp antibodies.
MX2013007168A (en) Anti-pcsk9 antibodies and methods of use.
IN2014DN05885A (en)
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
MX340555B (en) Antibodies against il-18r1 and uses thereof.
AU337887S (en) Allsaw
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
MX357675B (en) Anti-jagged anitbodies and methods of use.
WO2013123046A3 (en) Cathode buffer materials and related devices and methods
PH12015501854A1 (en) Factor ix polypeptide formulations
UA112760C2 (en) THEOBROMIN IN COMBINATION WITH GUYPHENESINE FOR THE TREATMENT OF Cough
MX2023003000A (en) Modified release formulations of viloxazine.
IN2015DN00820A (en)
AU337888S (en) Allsaw
GB201114923D0 (en) Immunogenic proteins and compositions